Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$1.96
-0.5%
$1.98
$1.36
$3.38
$9.53M1.5715,829 shs11,583 shs
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
$2.84
+1.4%
$3.01
$1.38
$3.50
$15.82M-1.2119,017 shs7,951 shs
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$8.15
+2.1%
$8.39
$5.01
$10.75
$10.47M0.88173,014 shs1,817 shs
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
$2.38
$2.07
$10.85
$61.05MN/A171,558 shs43,600 shs
Tocagen Inc stock logo
TOCA
Tocagen
$0.72
-2.7%
$32.24
$0.42
$6.77
$17.22M0.011.47 million shs14,300 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
+0.51%0.00%-0.50%+5.88%-38.70%
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
+3.32%-2.55%-8.79%+5.26%+11.11%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
-2.11%-1.62%-12.32%+53.10%+32.60%
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
0.00%0.00%0.00%0.00%0.00%
Tocagen Inc stock logo
TOCA
Tocagen
-0.01%-2.72%+2.78%+5.87%-31.44%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
1.8795 of 5 stars
3.55.00.00.00.60.00.6
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
2.2212 of 5 stars
3.50.00.03.40.00.00.6
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
3.00
Buy$15.00665.31% Upside
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
3.00
Buy$5.0076.06% Upside
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
2.00
HoldN/AN/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
N/AN/AN/AN/A

Current Analyst Ratings

Latest HTBX, AYTU, AEZS, GHSI, and TOCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/2/2024
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$4.50M2.12N/AN/A$3.75 per share0.52
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
$107.40M0.15$1.03 per share2.75$10.41 per share0.27
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.85$0.14 per share59.51$6.39 per share1.28
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
$40K430.48N/AN/A$0.45 per share1.60

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
-$16.55M-$3.41N/AN/A-368.01%-63.20%-37.35%5/14/2024 (Estimated)
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
-$17.05M-$4.04N/AN/A-18.27%-41.00%-10.87%5/9/2024 (Estimated)
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$0.1174.10N/A0.51%2.01%1.21%5/20/2024 (Estimated)
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/A

Latest HTBX, AYTU, AEZS, GHSI, and TOCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A$0.33+$0.33$0.33N/A$21.56 million
3/27/2024Q4 2023
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
-$0.97-$1.16-$0.19-$1.16N/A$0.12 million
2/14/2024Q2 2024
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
N/A-$0.04-$0.04-$0.04N/A$22.93 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/A
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
N/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/A
8.01
8.00
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
0.46
1.11
0.91
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
9.01
6.98
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/A
Tocagen Inc stock logo
TOCA
Tocagen
1.88
1.15
1.15

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.73%
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
33.49%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
20.21%
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/A
Tocagen Inc stock logo
TOCA
Tocagen
21.42%

Insider Ownership

CompanyInsider Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.10%
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
4.34%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
1.32%
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/A
Tocagen Inc stock logo
TOCA
Tocagen
10.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
114.86 million4.85 millionNo Data
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
1505.57 million5.33 millionNot Optionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
91.28 million1.27 millionNot Optionable
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
4925.65 millionN/AOptionable
Tocagen Inc stock logo
TOCA
Tocagen
7723.92 millionN/ANot Optionable

HTBX, AYTU, AEZS, GHSI, and TOCA Headlines

SourceHeadline
Glioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.biz
pharmiweb.com - March 25 at 4:25 AM
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline GliomaONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
ascopubs.org - February 12 at 6:14 PM
Miami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorsMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumors
eurekalert.org - January 20 at 12:14 AM
Forte Biosciences: Changes In Registrant S Certifying AccountantForte Biosciences: Changes In Registrant S Certifying Accountant
cbonds.com - December 12 at 8:27 AM
RiskOn International And 3 Other Stocks Under $2 Insiders Are BuyingRiskOn International And 3 Other Stocks Under $2 Insiders Are Buying
markets.businessinsider.com - December 11 at 9:20 AM
Precision and personalized medicine: the leading companies in personalized cancer vaccines revealedPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealed
pharmaceutical-technology.com - November 6 at 9:33 AM
ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board AppointmentProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment
finance.yahoo.com - November 2 at 10:33 AM
FDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma PatientsFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma Patients
precisionmedicineonline.com - July 26 at 11:09 PM
Gene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPR
news.google.com - May 12 at 8:33 AM
Form DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.com
news.google.com - April 29 at 12:45 AM
Genomic and transcriptomic analysis of checkpoint blockade ... - Nature.comGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.com
news.google.com - April 6 at 8:25 PM
Belzutifan plus cabozantinib for patients with advanced clear cell ... - The LancetBelzutifan plus cabozantinib for patients with advanced clear cell ... - The Lancet
news.google.com - March 31 at 11:10 PM
Current drug development and trial designs in neuro-oncology ... - The LancetCurrent drug development and trial designs in neuro-oncology ... - The Lancet
news.google.com - March 28 at 12:07 AM
Companion Diagnostics Market is set to experience a significant ... - Digital JournalCompanion Diagnostics Market is set to experience a significant ... - Digital Journal
news.google.com - March 27 at 8:37 AM
Oligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital JournalOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital Journal
news.google.com - March 14 at 4:44 PM
Anaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital JournalAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital Journal
news.google.com - March 8 at 10:39 AM
Anaplastic Oligoastrocytoma Market Focus On Estimation, Research ... - Taiwan NewsAnaplastic Oligoastrocytoma Market Focus On Estimation, Research ... - Taiwan News
news.google.com - March 2 at 1:05 PM
Anaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029Anaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029
marketwatch.com - February 28 at 3:22 AM
Companion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029Companion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029
marketwatch.com - February 27 at 9:31 AM
An echo through brain cancer’s empty pipelineAn echo through brain cancer’s empty pipeline
pharmaphorum.com - February 7 at 7:04 PM
Companion Diagnostics Market Size, Share, Growth Statistics By ... - Digital JournalCompanion Diagnostics Market Size, Share, Growth Statistics By ... - Digital Journal
news.google.com - February 3 at 6:12 AM
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer - Yahoo FinanceCardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer - Yahoo Finance
news.google.com - February 2 at 1:10 PM
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar ... - PR NewswireCardiff Oncology Announces the Appointment of Fairooz Kabbinavar ... - PR Newswire
news.google.com - February 2 at 8:09 AM
Human Resource Management Market Booming Worldwide With ... - Rejoice MagazineHuman Resource Management Market Booming Worldwide With ... - Rejoice Magazine
news.google.com - January 27 at 11:36 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aeterna Zentaris logo

Aeterna Zentaris

NASDAQ:AEZS
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Aytu BioPharma logo

Aytu BioPharma

NASDAQ:AYTU
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.
Guardion Health Sciences logo

Guardion Health Sciences

NASDAQ:GHSI
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
Heat Biologics logo

Heat Biologics

NASDAQ:HTBX
Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Tocagen logo

Tocagen

NASDAQ:TOCA
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.